T cell immunotherapy for cervical cancer: challenges and opportunities
Cancer cellular immunotherapy has made inspiring therapeutic effects in clinical practices, which brings new hope for the cure of cervical cancer. CD8+T cells are the effective cytotoxic effector cells against cancer in antitumor immunity, and T cells-based immunotherapy plays a crucial role in cell...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1105265/full |
| _version_ | 1797839094186770432 |
|---|---|
| author | Lingfeng Yu Gong Lanqing Ziyu Huang Xiaoyan Xin Liang Minglin Lv Fa-hui Hongmei Zou Jie Min |
| author_facet | Lingfeng Yu Gong Lanqing Ziyu Huang Xiaoyan Xin Liang Minglin Lv Fa-hui Hongmei Zou Jie Min |
| author_sort | Lingfeng Yu |
| collection | DOAJ |
| description | Cancer cellular immunotherapy has made inspiring therapeutic effects in clinical practices, which brings new hope for the cure of cervical cancer. CD8+T cells are the effective cytotoxic effector cells against cancer in antitumor immunity, and T cells-based immunotherapy plays a crucial role in cellular immunotherapy. Tumor infiltrated Lymphocytes (TIL), the natural T cells, is approved for cervical cancer immunotherapy, and Engineered T cells therapy also has impressive progress. T cells with natural or engineered tumor antigen binding sites (CAR-T, TCR-T) are expanded in vitro, and re-infused back into the patients to eradicate tumor cells. This review summarizes the preclinical research and clinical applications of T cell-based immunotherapy for cervical cancer, and the challenges for cervical cancer immunotherapy. |
| first_indexed | 2024-04-09T15:52:41Z |
| format | Article |
| id | doaj.art-1d16c561020d4ad68ef0f1895f01e74b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T15:52:41Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-1d16c561020d4ad68ef0f1895f01e74b2023-04-26T05:21:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-04-011410.3389/fimmu.2023.11052651105265T cell immunotherapy for cervical cancer: challenges and opportunitiesLingfeng Yu0Gong Lanqing1Ziyu Huang2Xiaoyan Xin3Liang Minglin4Lv Fa-hui5Hongmei Zou6Jie Min7School of Basic Medical Sciences, Tianjin Medical University, Tianjin, ChinaDepartment of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaSchool of Arts and Sciences, Brandeis University, Boston, MA, United StatesSchool of Arts and Sciences, Brandeis University, Boston, MA, United StatesSchool of Arts and Sciences, Brandeis University, Boston, MA, United StatesDepartment of Obstetrics and Gynecology, The Second People’s Hospital of Hefei, Hefei, Anhui, ChinaDepartment of Obstetrics, Qianjiang Central Hospital, Qianjiang, Hubei, ChinaDepartment of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCancer cellular immunotherapy has made inspiring therapeutic effects in clinical practices, which brings new hope for the cure of cervical cancer. CD8+T cells are the effective cytotoxic effector cells against cancer in antitumor immunity, and T cells-based immunotherapy plays a crucial role in cellular immunotherapy. Tumor infiltrated Lymphocytes (TIL), the natural T cells, is approved for cervical cancer immunotherapy, and Engineered T cells therapy also has impressive progress. T cells with natural or engineered tumor antigen binding sites (CAR-T, TCR-T) are expanded in vitro, and re-infused back into the patients to eradicate tumor cells. This review summarizes the preclinical research and clinical applications of T cell-based immunotherapy for cervical cancer, and the challenges for cervical cancer immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1105265/fullcervical cancerengineered T cellsTILsTCR-TsCAR-Tsimmune checkpoint |
| spellingShingle | Lingfeng Yu Gong Lanqing Ziyu Huang Xiaoyan Xin Liang Minglin Lv Fa-hui Hongmei Zou Jie Min T cell immunotherapy for cervical cancer: challenges and opportunities Frontiers in Immunology cervical cancer engineered T cells TILs TCR-Ts CAR-Ts immune checkpoint |
| title | T cell immunotherapy for cervical cancer: challenges and opportunities |
| title_full | T cell immunotherapy for cervical cancer: challenges and opportunities |
| title_fullStr | T cell immunotherapy for cervical cancer: challenges and opportunities |
| title_full_unstemmed | T cell immunotherapy for cervical cancer: challenges and opportunities |
| title_short | T cell immunotherapy for cervical cancer: challenges and opportunities |
| title_sort | t cell immunotherapy for cervical cancer challenges and opportunities |
| topic | cervical cancer engineered T cells TILs TCR-Ts CAR-Ts immune checkpoint |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1105265/full |
| work_keys_str_mv | AT lingfengyu tcellimmunotherapyforcervicalcancerchallengesandopportunities AT gonglanqing tcellimmunotherapyforcervicalcancerchallengesandopportunities AT ziyuhuang tcellimmunotherapyforcervicalcancerchallengesandopportunities AT xiaoyanxin tcellimmunotherapyforcervicalcancerchallengesandopportunities AT liangminglin tcellimmunotherapyforcervicalcancerchallengesandopportunities AT lvfahui tcellimmunotherapyforcervicalcancerchallengesandopportunities AT hongmeizou tcellimmunotherapyforcervicalcancerchallengesandopportunities AT jiemin tcellimmunotherapyforcervicalcancerchallengesandopportunities |